XML 35 R36.htm IDEA: XBRL DOCUMENT v2.4.0.6
U.S. Government Agreement and Collaborations (Details) (USD $)
 3 Months Ended 9 Months Ended 1 Months Ended 9 Months Ended 20 Months Ended 1 Months Ended 3 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Feb. 28, 2011
Feb. 28, 2011
HHS BARDA Contract Award [Member]
Sep. 30, 2012
HHS BARDA Contract Award [Member]
Sep. 30, 2011
HHS BARDA Contract Award [Member]
Sep. 30, 2012
HHS BARDA Contract Award [Member]
Feb. 28, 2011
HHS BARDA Option for Additional Period [Member]
Feb. 28, 2011
License Agreement with LG Life Sciences, Ltd. [Member]
Feb. 28, 2011
License Agreement with LG Life Sciences, Ltd. [Member]
Minimum [Member]
Feb. 28, 2011
License Agreement with LG Life Sciences, Ltd. [Member]
Maximum [Member]
Sep. 30, 2012
PATH Vaccine Solutions [Member]
Jul. 31, 2012
PATH Vaccine Solutions [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Contract receivable         $ 179,000,000 $ 97,000,000       $ 82,000,000         $ 2,000,000
Contract term           36 months       24 months          
Government contracts 5,583,000 5,008,000 17,328,000 8,843,000       16,900,000 31,600,000            
Research and development collaboration 182,000    182,000                      200,000  
Expected costs             3,100,000   3,100,000            
Trial costs incurred             2,800,000                
Upfront license payment                     $ 2,500,000        
Royalty payments, percent                       10.00% 20.00%    
Potential funding of external clinical development costs                             50.00%